A French biopharma company has announced their plans to carry out human trials of a new treatment that would insert genes from light-seeking algae into the eyes of patients with inherited blindness in order to help them regain sight. The treatment involves optogenetics, a technique that converts nerve cells into light sensitive cells. Although optogenetics is commonly used in animal experiments, its effects on humans are far less known.
You must be logged in to post a comment.